Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.68 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.68 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.68 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.68 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.68 |
| ▸ | LDHA | P00338 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 1/20 | 0.68 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.68 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723484 | 0.91 | P2RY1 (0.70) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL3699269 | 0.90 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL6569310 | 0.88 | ADORA1 (0.73) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL4356493 | 0.88 | P2RY1 (0.66) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL381173 | 0.88 | P2RY1 (0.66) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL939593 | 0.87 | ADORA1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL8708990 | 0.87 | ADORA1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL28978257 | 0.87 | P2RY1 (0.65) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL5327610 | 0.86 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL926920 | 0.86 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263762-B2 | Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2448953-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THATREOF AS A2AR AGONISTS | Forest Laboratories Holdings Limited (BM) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002917-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2A R AGONISTS | PGXHEALTH, LLC (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003766-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003766-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | P2RY1 28/4885ADORA1 3/4885P2RY2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.